Carabell S C, Chaffey J T, Rosenthal D S, Moloney W C, Hellman S
Cancer. 1979 Mar;43(3):994-1000. doi: 10.1002/1097-0142(197903)43:3<994::aid-cncr2820430331>3.0.co;2-0.
Total body irradiation (TBI) was used as primary therapy for 58 previously untreated patients with Stage III or IV non-Hodgkin's lymphoma (NHL). 150 rad was administered, with 15 rad fractions twice a week, with careful monitoring of hematologic status. Thrombocytopenia was the most frequent complication, which resolved in all except 4 patients. Survival at 8 years was 52%, with 14% relapse-free survival. Patients with nodular histology had a more favorable prognosis than those with diffuse histology (median relapse-free survival of 24 vs. 12 months). There were 2 cases of erythroleukemia, which occurred after combination chemotherapy was given for relapse. Though TBI can offer complete remission and extended survival in advanced NHL, most patients eventually relapse and it should not be considered as a curative mode of therapy.
全身照射(TBI)被用作58例先前未经治疗的Ⅲ期或Ⅳ期非霍奇金淋巴瘤(NHL)患者的主要治疗方法。给予150拉德的剂量,每周两次,每次15拉德,同时密切监测血液学状态。血小板减少是最常见的并发症,除4例患者外,其余均已缓解。8年生存率为52%,无复发生存率为14%。结节性组织学类型的患者预后比弥漫性组织学类型的患者更好(无复发生存期的中位数分别为24个月和12个月)。有2例红白血病,发生在复发后进行联合化疗时。虽然TBI可以使晚期NHL患者实现完全缓解并延长生存期,但大多数患者最终仍会复发,因此不应将其视为一种治愈性的治疗方式。